In this investigation, we tried to find the incidence and characteristics of tuberculosis (TB) in dialysis patients previously found only in a small number of cases. We collected the cases of newly diagnosed TB patients in Taiwan during 1997. Simultaneously, all dialysis patients were collected and matched with the TB cases to identify the dialysis patients who had also contracted TB. The annual incidence of the dialysis population was 493.4/100,000, 6.9 times that of the general population (71.1/100,000). The annual incidence for the male dialysis population was 573.3, the incidence was 479.2 for the female dialysis population. The incidence for the general population was 97.1 and 43.7/100,000, respectively. Although the 1-year mortality rate due to TB (1.7 vs. 1.9%, p > 0.05) was similar in both populations, the non-TB mortality was much higher in the dialysis population than that in the general population (25.6 vs. 11.1%, p < 0.05). Finally, the 1-year mortality rate of dialysis patients with TB is 3.3 times higher than that in dialysis patients without TB (27.3 vs. 8.3%, p < 0.05). The findings suggest that uremia modifies the behavior of TB, jeopardizes female and younger dialysis patients, poses a higher risk of extrapulmonary dissemination, and predicts a higher overall mortality.

Keywords:
Tuberculosis, Uremia, Dialysis
1.
Lienhardt C, Sow S: The global challenge of tuberculosis. Lancet 1994;344:277–279.
2.
Newberry WM, Sanford JP: Defective cellular immunity in renal failure: Depression of reactivity of lymphocytes to phytohemagglutinin by renal failure serum. J Clin Invest 1971;50:1262–1271.
3.
Nakhla LS, Goggin MJ: Lymphocyte transformation in chronic renal failure. Immunology 1973;24:229–235.
4.
Silk MR: The effect of uremic plasma on lymphocyte transformation. Invest Urol 1967;5:195–199.
5.
Selroos O, Pasternack A, Virolainen M: Skin test sensitivity and antigen-induced lymphocyte transformation in uraemia. Clin Exp Immunol 1973;14:365–370.
6.
Lundin AP, Adler AJ, Berlyne GM, Friedman EA: Tuberculosis in patients undergoing maintenance hemodialysis. Am J Med 1979;67:597–602.
7.
Andrew OT, Schoenfeld PY, Hopewell PC, Humphreys MH: Tuberculosis in patients with end-stage renal disease. Am J Med 1980;68:59–65.
8.
Belcon MC, Smith EK, Kahana LM, Shimizu AG: Tuberculosis in dialysis patients. Clin Nephrol 1982;17:14–18.
9.
Leu ML, Lin JL, Wu CH, Huang CC: Tuberculosis in uremic patients (Chinese). Taiwan I Hsueh Hui Tsa Chih 1988;87:1202–1207.
10.
Zhang X, Hou F, Wei D: Tuberculosis in chronic renal failure patients with or without renal replacement therapy (Chinese). Chung Hua Nei Ko Tsa Chih 1995;34:666–669.
11.
Shohaib SA, Scrimgeour EM, Shaerya F: Tuberculosis in active dialysis patients in Jeddah. Am J Nephrol 1999;19:34–37.
12.
Clark TJ, Richards NT, Adu D, Michael J: Increased prevalence of dialysis-dependent renal failure in ethnic minorities in the West Midlands. Nephrol Dial Transplant 1993;8:146–148.
13.
Van den Broek J, Borgdorff MW, Pakker NG, et al: HIV-1 infection as a risk factor for the development of tuberculosis: A case-control study in Tanzania. Int J Epidemiol 1993;22:1159–1165.
14.
Freeman R, Newhouse CE, Lawton RL: Absence of tuberculosis in dialysis patients. JAMA 1975;233:1356.
15.
Hsu KT, Lam KK, Liao SC, et al: Prevalence of pulmonary tuberculosis in end-stage renal disease patients is not unusually high. Clin Nephrol 1996;45:279–280.
16.
Tolkoff-Rubin NE, Rubin RH: Uremia and host defenses. N Engl J Med 1990;322:770–772.
17.
Huber H, Pastner D, Dittrich P, Braunsteiner H: In vitro reactivity of human lymphocytes in uraemia – A comparison with the impairment of delayed hypersensitivity. Clin Exp Immunol 1969;5:75–82.
18.
Byron PR, Mallick NP, Taylor G: Immune potential in human uraemia. 2. Changes after regular haemodialysis therapy. J Clin Pathol 1976;29:770–772.
19.
Papadimitriou M, Memmos D, Metaxas P: Tuberculosis in patients on regular haemodialysis. Nephron 1979;24:53–57.
20.
Woods GL, Washington JA, 2nd: Mycobacteria other than Mycobacterium tuberculosis: Review of microbiologic and clinical aspects. Rev Infect Dis 1987;9:275–294.
© 2001 S. Karger AG, Basel
2001
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.